Protagonist Therapeutics, Inc. (PTGX)
134.58
+5.83
(+4.53%)
USD |
NASDAQ |
Oct 19, 16:00
134.58
0.00 (0.00%)
After-Hours: 20:00
Protagonist Therapeutics EPS Diluted (Quarterly) : 2.293 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.293 |
| March 31, 2026 | 0.0537 |
| December 31, 2025 | -0.6932 |
| September 30, 2025 | -0.6169 |
| June 30, 2025 | -0.5475 |
| March 31, 2025 | -0.1851 |
| December 31, 2024 | 1.983 |
| September 30, 2024 | -0.5377 |
| June 30, 2024 | -0.4994 |
| March 31, 2024 | 3.260 |
| December 31, 2023 | 0.4423 |
| September 30, 2023 | -0.5763 |
| June 30, 2023 | -0.6774 |
| March 31, 2023 | -0.6669 |
| December 31, 2022 | -0.6941 |
| September 30, 2022 | -0.636 |
| June 30, 2022 | -0.8366 |
| March 31, 2022 | -0.4293 |
| December 31, 2021 | -0.7664 |
| September 30, 2021 | -0.7044 |
| June 30, 2021 | -0.6874 |
| March 31, 2021 | -0.5426 |
| Date | Value |
|---|---|
| December 31, 2020 | -0.4769 |
| September 30, 2020 | -0.2076 |
| June 30, 2020 | -0.5921 |
| March 31, 2020 | -0.7248 |
| December 31, 2019 | -0.6338 |
| September 30, 2019 | -0.6087 |
| June 30, 2019 | -1.183 |
| March 31, 2019 | -0.5804 |
| December 31, 2018 | -0.5733 |
| September 30, 2018 | -0.3812 |
| June 30, 2018 | -0.41 |
| March 31, 2018 | -0.3629 |
| December 31, 2017 | -0.15 |
| September 30, 2017 | -0.29 |
| June 30, 2017 | -0.89 |
| March 31, 2017 | -0.84 |
| December 31, 2016 | -0.67 |
| September 30, 2016 | -0.87 |
| June 30, 2016 | -0.4449 |
| March 31, 2016 | -0.6755 |
| March 31, 2015 | -0.1546 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Johnson & Johnson | 0.0858 |
| AbbVie, Inc. | 2.033 |
| Gilead Sciences, Inc. | -8.444 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| BioMarin Pharmaceutical, Inc. | 0.2302 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 162.85M |
| Revenue (Quarterly) | 213.48M |
| Total Expenses (Quarterly) | 50.63M |
| Enterprise Value | 7.553B |
| Gross Profit Margin (Quarterly) | 99.81% |
| Profit Margin (Quarterly) | 76.28% |
| Earnings Yield | 0.77% |
| Operating Earnings Yield | 0.64% |
| Normalized Earnings Yield | 0.7706 |